US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Simplify High Yield ETF

21.03

-0.0550-0.26%

Post-market: 21.030.00000.00%16:10 EDT

Volume:102.69K

Turnover:2.16M

Market Cap:394.31M

PE:- -

High:21.16

Open:21.14

Low:21.03

Close:21.09

52wk High:23.35

52wk Low:21.02

Shares:18.75M

Float Shares:18.75M

Volume Ratio:0.78

T/O Rate:0.55%

Dividend:1.76

Dividend Rate:8.37%

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Concept

no data

No relevant data is available

Capital Flow

Inflow:

Outflow:

News

Celldex presents first-in-human results for CDX-622

Press Release: BioLineRx Reports First Quarter 2026 Financial Results and Provides Corporate Update

BioLineRx Drug Shows Anti-Tumor Activity In Brain Tumor Animal Models

Junshi Biosciences Presents Results from JS207 (PD-1/VEGF BsAb) Phase 2 Combo Studies and JS212 (EGFR/HER3 ADC) FIH Phase 1/2 Study at AACR 2026

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/CDX"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"CDX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CDX\",,,,,undefined,":{"symbol":"CDX","market":"US","secType":"STK","nameCN":"Simplify High Yield ETF","latestPrice":21.03,"timestamp":1782504000000,"preClose":21.085,"halted":0,"volume":102691,"hourTrading":{"tag":"盘后","latestPrice":21.03,"preClose":21.03,"latestTime":"16:10 EDT","volume":11,"amount":231.33,"timestamp":1782504605028,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.0026084894474744944,"floatShares":18750001,"shares":18750001,"eps":0,"marketStatus":"Post-Mkt","change":-0.055,"latestTime":"06-26 17:30:11 EDT","open":21.14,"high":21.16,"low":21.03,"amount":2162894,"amplitude":0.006166,"askPrice":23.24,"askSize":100,"bidPrice":21.01,"bidSize":1,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1782518400000},"marketStatusCode":4,"adr":0,"exchange":"ARCA","adjPreClose":21.085,"sharesOutstanding":22225001,"nav":21.2208,"aum":400011881.17,"dividendRate":0.083728,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":21.03,"preClose":21.03,"latestTime":"16:10 EDT","volume":11,"amount":231.33,"timestamp":1782504605028,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.779738},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CDX\",,,,,undefined,":{"symbol":"CDX","floatShares":18750001,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.779738,"shares":18750001,"dividePrice":1.7608,"high":21.16,"amplitude":0.006166,"preClose":21.085,"low":21.03,"week52Low":21.02,"pbRate":"--","week52High":23.35,"institutionHeld":0,"latestPrice":21.03,"committee":-0.980198,"eps":0,"divideRate":0.083728,"volume":102691,"delay":0,"ttmEps":0,"open":21.14,"prevYearClose":22.27,"prevWeekClose":21.245,"prevMonthClose":21.14,"prevQuarterClose":21.34,"fiveDayClose":21.245,"twentyDayClose":21.1,"sixtyDayClose":21.34},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/CDX\",params:#limit:5,,,undefined,":[{"date":"2026-06-25","symbol":"CDX","amount":0.13,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-06-25","defaultRemindTime":1782394200000,"name":"Simplify High Yield ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-06-30","payableDate":"2026-06-25","currency":"USD","dateTimestamp":1782360000000,"payDate":"2026-06-30"},{"date":"2026-05-26","symbol":"CDX","amount":0.12,"announcedDate":"2026-05-22","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-05-26","defaultRemindTime":1779802200000,"name":"Simplify High Yield ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-05-29","payableDate":"2026-05-26","currency":"USD","dateTimestamp":1779768000000,"payDate":"2026-05-29"},{"date":"2026-04-27","symbol":"CDX","amount":0.14,"announcedDate":"2026-04-24","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-04-27","defaultRemindTime":1777296600000,"name":"Simplify High Yield ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-04-30","payableDate":"2026-04-27","currency":"USD","dateTimestamp":1777262400000,"payDate":"2026-04-30"},{"date":"2026-03-26","symbol":"CDX","amount":0.15,"announcedDate":"2026-03-25","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-03-26","defaultRemindTime":1774531800000,"name":"Simplify High Yield ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-03-31","payableDate":"2026-03-26","currency":"USD","dateTimestamp":1774497600000,"payDate":"2026-03-31"},{"date":"2026-02-24","symbol":"CDX","amount":0.15,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-02-24","defaultRemindTime":1771943400000,"name":"Simplify High Yield ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-02-27","payableDate":"2026-02-24","currency":"USD","dateTimestamp":1771909200000,"payDate":"2026-02-27"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"CDX\",market:\"US\",,,undefined,":[{"executeDate":"2022-03-28","recordDate":"2022-03-29","paymentDate":"2022-03-31","value":0.0631,"currency":"USD"},{"executeDate":"2022-04-26","recordDate":"2022-04-27","paymentDate":"2022-04-29","value":0.08882,"currency":"USD"},{"executeDate":"2022-05-25","recordDate":"2022-05-26","paymentDate":"2022-05-31","value":0.10303,"currency":"USD"},{"executeDate":"2022-06-27","recordDate":"2022-06-28","paymentDate":"2022-06-30","value":0.09614,"currency":"USD"},{"executeDate":"2022-07-26","recordDate":"2022-07-27","paymentDate":"2022-07-29","value":0.06047,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"CDX\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"CDX\",pageSize:4,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2643247739","title":"Celldex presents first-in-human results for CDX-622","url":"https://stock-news.laohu8.com/highlight/detail?id=2643247739","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643247739?lang=en_us&edition=fundamental","pubTime":"2026-06-15 04:50","pubTimestamp":1781470228,"startTime":"0","endTime":"0","summary":"Celldex (CLDX) presented positive results from the Phase 1 healthy participant study of CDX-622 at the European Academy of Allergy and Clinical Imm...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/celldex-presents-first-in-human-results-for-cdx-622-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/celldex-presents-first-in-human-results-for-cdx-622-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CDX","EPV","CLDX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638048955","title":"Press Release: BioLineRx Reports First Quarter 2026 Financial Results and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2638048955","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638048955?lang=en_us&edition=fundamental","pubTime":"2026-05-27 19:00","pubTimestamp":1779879600,"startTime":"0","endTime":"0","summary":"- Announced first patient dosed in Phase 1/2a clinical trial of GLIX1 for treatment of glioblastoma  -. - Announced new GLIX1 data demonstrating potent anti-tumor effect in GBM across multiple in-vivo studies, including a temozolomide -resistant patient-derived xenograft model -. - Management to host conference call today, May 27, at 8:30 am EDT -. TEL AVIV, Israel, May 27, 2026 /PRNewswire/ -- BioLineRx Ltd.  , a clinical-stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today reported its unaudited financial results for the quarter ended March 31, 2026, and provided a corporate update.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4211","BK4533","PDX","BLRX","BK4548","BK4139","LU1093756325.SGD","BK4585","LU2413666426.HKD","LU1093756168.USD","BK4567","LU2413666699.HKD","BK4232","IE00B5TLWC47.USD","BK4121","BK4022","IE00BYQQ9H92.USD","BK4588","LU0347712357.USD","MTD","BK4195","IE00BFXG0V08.USD","LU1721428933.USD","LU2211817866.USD","PFS","R","CDX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636860229","title":"BioLineRx Drug Shows Anti-Tumor Activity In Brain Tumor Animal Models","url":"https://stock-news.laohu8.com/highlight/detail?id=2636860229","media":"Benzinga","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636860229?lang=en_us&edition=fundamental","pubTime":"2026-05-20 06:28","pubTimestamp":1779229680,"startTime":"0","endTime":"0","summary":"BioLineRx, a commercial-stage biopharmaceutical company focused on oncology, and Hemispherian revealed new preclinical data showing GLIX1’s strong anti-tumor activity, even in a temozolomide -resistant model.In the threeorthotopic cell-derived xenograft  studies,significant tumor growth inhibition and survival benefit were observed following treatment with GLIX1 across all doses tested, with greater benefit at higher dose levels.In these models,mice treated with TMZ also showed significantly decreased tumor volume and survival benefit.Most notably, inthe subcutaneous PDX model, GLIX1 demonstrated a robust anti-tumor effect while TMZ showed no effect.The finding highlights the potential of GLIX1 to address the significant unmet needs of patients suffering from glioblastoma, an aggressive form of cancer.In April, BioLineRx initiated a first-in-human, Phase 1/2a study of GLIX1 for the treatment of recurrent and progressive GBM and other high-grade glioma.BLRX Price Action: BioLine Rx shar","market":"us","thumbnail":"https://cdn.benzinga.com/cdn-cgi/image/width=630,dpr=2,format=auto,quality=85/files/images/story/2026/05/19/Cancer---Heart-Shape-To-Represent-Medica.jpeg","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/cdn-cgi/image/width=630,dpr=2,format=auto,quality=85/files/images/story/2026/05/19/Cancer---Heart-Shape-To-Represent-Medica.jpeg"],"rights":{"source":"benzinga_hot_news","url":"https://www.benzinga.com/markets/biotech/26/05/52680140/biolinerx-drug-shows-anti-tumor-activity-in-brain-tumor-animal-models","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/markets/biotech/26/05/52680140/biolinerx-drug-shows-anti-tumor-activity-in-brain-tumor-animal-models","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_hot_news","symbols":["CDX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629877995","title":"Junshi Biosciences Presents Results from JS207 (PD-1/VEGF BsAb) Phase 2 Combo Studies and JS212 (EGFR/HER3 ADC) FIH Phase 1/2 Study at AACR 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2629877995","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629877995?lang=en_us&edition=fundamental","pubTime":"2026-04-21 05:00","pubTimestamp":1776718800,"startTime":"0","endTime":"0","summary":"SHANGHAI, April  20, 2026 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/04/20/3277510/0/en/Junshi-Biosciences-Presents-Results-from-JS207-PD-1-VEGF-BsAb-Phase-2-Combo-Studies-and-JS212-EGFR-HER3-ADC-FIH-Phase-1-2-Study-at-AACR-2026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4006","BK4585","BK4548","BK4567","BK4211","BK4121","BK4195","BK1508","LU0347712357.USD","BK4533","LU1093756168.USD","PFS","PR","LU1169589451.USD","IND","LU1169590202.USD","BK1167","ADC","BK4588","SD","BK4023","LU2413666699.HKD","02038","IE00BYQQ9H92.USD","BK4080","ORR","LU2413666426.HKD","HCC","LU1093756325.SGD","BK1504","IE00B5TLWC47.USD","LU2211817866.USD","BK4213","CDX","MTD","IE00BFXG0V08.USD","BK4231","LU1721428933.USD","PD"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":4,"totalPage":2,"pageCount":1,"totalSize":5,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/CDX\",params:#limit:6,delay:false,,,undefined,":[]}}